share_log

Mangoceuticals | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Mangoceuticals | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Mangoceuticals | PRE 14A:並購重組委托聲明
美股SEC公告 ·  05/06 16:45

Moomoo AI 已提取核心訊息

Mangoceuticals, Inc. has announced a series of significant corporate events, including the issuance of Series B Convertible Preferred Stock and associated Warrants, an Equity Line of Credit (ELOC) agreement, and the acquisition of patents through the issuance of Series C Convertible Preferred Stock. The company has entered into a Securities Purchase Agreement (SPA) with an institutional accredited investor to sell Series B Preferred Stock and Warrants, potentially resulting in the issuance of more than 20% of the company's outstanding common stock. Additionally, the ELOC agreement with the same investor could see the sale of common stock up to $25 million, subject to stockholder approval due to the potential issuance exceeding 20% of the outstanding shares. Furthermore, Mangoceuticals has acquired patents related to...Show More
Mangoceuticals, Inc. has announced a series of significant corporate events, including the issuance of Series B Convertible Preferred Stock and associated Warrants, an Equity Line of Credit (ELOC) agreement, and the acquisition of patents through the issuance of Series C Convertible Preferred Stock. The company has entered into a Securities Purchase Agreement (SPA) with an institutional accredited investor to sell Series B Preferred Stock and Warrants, potentially resulting in the issuance of more than 20% of the company's outstanding common stock. Additionally, the ELOC agreement with the same investor could see the sale of common stock up to $25 million, subject to stockholder approval due to the potential issuance exceeding 20% of the outstanding shares. Furthermore, Mangoceuticals has acquired patents related to infection prevention from Intramont Technologies, Inc., compensated with Series C Preferred Stock valued at $19.6 million and cash payments totaling $400,000. The transactions involving Series B and C Preferred Stock and the ELOC are subject to stockholder approval in compliance with Nasdaq Listing Rules 5635(a) and (d). The company is also seeking ratification for the appointment of Turner, Stone & Company, L.L.P. as its independent auditor for the fiscal year ending December 31, 2024. Lastly, a proposal to adjourn the annual meeting to solicit additional proxies for the aforementioned transactions if necessary has been put forth. These strategic moves are aimed at bolstering Mangoceuticals' financial position and expanding its product offerings in the healthcare sector.
Mangoceuticals, Inc. 宣佈了一系列重大公司活動,包括髮行B系列可轉換優先股和相關認股權證、股票信貸額度(ELOC)協議以及通過發行C系列可轉換優先股收購專利。該公司已與一家機構認可的投資者簽訂了證券購買協議(SPA),出售B系列優先股和認股權證,這可能導致該公司20%以上的已發行普通股的發行。此外,與同一投資者簽訂的ELOC協議可能會出售高達2500萬美元的普通股,但須經股東批准,因爲其發行量可能超過已發行股票的20%。此外,Mangoceuticals已從Intramont Technologies, Inc. 獲得了與感染預防相關的專利,補償了價值1,960萬美元的C輪...展開全部
Mangoceuticals, Inc. 宣佈了一系列重大公司活動,包括髮行B系列可轉換優先股和相關認股權證、股票信貸額度(ELOC)協議以及通過發行C系列可轉換優先股收購專利。該公司已與一家機構認可的投資者簽訂了證券購買協議(SPA),出售B系列優先股和認股權證,這可能導致該公司20%以上的已發行普通股的發行。此外,與同一投資者簽訂的ELOC協議可能會出售高達2500萬美元的普通股,但須經股東批准,因爲其發行量可能超過已發行股票的20%。此外,Mangoceuticals已從Intramont Technologies, Inc. 獲得了與感染預防相關的專利,補償了價值1,960萬美元的C輪優先股和總額爲40萬美元的現金支付。根據納斯達克上市規則5635(a)和(d),涉及B和C系列優先股以及ELOC的交易須經股東批准。該公司還在尋求批准任命Turner, Stone & Company, L.L.P. 爲截至2024年12月31日的財政年度的獨立核數師。最後,有人提議休會,必要時爲上述交易尋求更多代理人。這些戰略舉措旨在鞏固Mangoceuticals的財務狀況並擴大其在醫療保健領域的產品供應。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息